Tamtam Try Tamtam free
Zimmer Biomet logo

Zimmer Biomet account plan

global medical technology leader

At a glance

Zimmer Biomet is a U.S. orthopedic medical technology company (knees, hips, S.E.T., ROSA robotics) with FY2025 net sales of $8,231.5 million.

Zimmer Biomet designs, manufactures and markets orthopedic reconstructive products (knees, hips), sports medicine, biologics, extremities and trauma, craniomaxillofacial and thoracic (CMFT) products, bone cement, surgical products and the ZBEdge digital and robotic platform, including the ROSA Robot. Its customers are orthopedic surgeons, neurosurgeons, hospitals, ambulatory surgery centers, stocking distributors and group purchasing organizations; consignment sales were approximately 85% of net sales in 2025. Its history dates to 1927 in Warsaw, Indiana. In FY2025 net sales were $8,231.5 million (+7.2%) and net earnings $705.1 million, with about 17,000 employees (7,000 in the U.S.) at December 31, 2025. Main competitors named are Johnson & Johnson MedTech, Stryker and Smith & Nephew.

Business units

Strategic priorities

U.S. sales force conversion (Project Optima)
Converting the U.S. sales force from independent representatives to a dedicated, specialised organisation, with completion targeted for the end of 2027. By Q3 2026 over 75% of the U.S. force was fully dedicated, three quarters into an eight-quarter journey, with 200 tech reps being added.
Fix knees through execution and robotics
Knees fell 3.1% in Q3 2026, with about 90% of the underperformance attributed to commercial execution. The plan combines new incentive plans and leadership with innovation: ROSA Optimize, the TMINI partnership and Monogram, whose fully autonomous version could launch in the first half of 2027.
Shift the mix to faster-growing markets
Management aims for a weighted average market growth rate (WAMGR) of 5%-6% by the end of the decade, by moving 85% to 90% of R&D into markets growing more than 5-6% and through M&A. Over 50 new products are expected in the next 36 months.
Cost and operating efficiency
The 2025 Restructuring Plan targets about $175 million of gross annual pre-tax opex savings vs 2024 by end-2027. Opex at about 46% of sales is to be addressed through AI, shared services and a global capability center in India.
M&A from 2027
After a 2026 focused on buybacks, deals of up to $2 billion each in higher-growth recon, S.E.T. and adjacencies such as the ASC environment, immediately revenue and WAMGR accretive and EPS accretive by year two.

Latest results

In Q3 2026 (quarter to September 30, 2026) net sales were $2,062.9 million, +3.1% reported and +3.7% constant currency; nine-month sales were $6,326.6 million (+5.7%). Hips grew 6.0%, S.E.T. 6.8% and Technology & Data, Bone Cement and Surgical 11.9%, while Knees fell 3.1% on the U.S. sales force transition, competition and the distributor transition in China. Q3 net earnings were $191.6 million vs $230.9 million, and operating profit was 14.9% of sales vs 17.6% a year earlier. The 2026 outlook was raised to net sales growth of 4.4% to 4.9%, organic constant-currency growth of 3% to 3.5% and adjusted EPS of $8.50 to $8.60.

Investments and deals

Paragon 28 and Monogram acquisitions
Paragon 28 (foot and ankle) acquired April 21, 2025 and Monogram Technologies (robotics) on October 7, 2025; $1,393.2 million was paid for the two in 2025. Paragon 28 grew over 18% in Q3 2026.
Three 2026 acquisitions
Iovera (non-surgical pain management, July 31, 2026, $74.6 million cash), Monteris Medical (laser therapy for brain tumors and epilepsy, August 11, 2026, $193.3 million cash) and Alafair Biosciences (soft-tissue protection device, August 24, 2026, $112.6 million cash), each with contingent payments.
Manufacturing network
A Manufacturing Network Optimization Plan started in September 2026 (about $60 million of exit costs by end-2028) consolidates U.S. sites into Warsaw, Indiana; a new manufacturing facility is under construction in Costa Rica.
Musculoskeletal investment fund
Commitment of up to $300 million to a fund focused on musculoskeletal and rheumatologic innovations, as exclusive orthopedic investor in the Deerfield Management and HSS Mobility Revolution Fund.
Share buybacks
A $1.5 billion buyback was authorised on February 9, 2026; $579.3 million of shares were repurchased in the first nine months of 2026, with $924.7 million left.

Challenges and risks

Sales force transition risk
The conversion is now early in its higher-risk third stage; the 10-K names loss of distributors and reps to competitors, coverage gaps and lower sales as risks.
China distributor consolidation
The China distributor transition weighs on growth (roughly 50 bp for 2026); China is 2% of revenue and 1% of EBITDA, and displaced distributors have raised legal claims.
Margin pressure
Adjusted operating margin was 25.1% in Q3 2026, down 140 bp on U.S. commercial investment; pricing was a 70 bp headwind.
Debt and tariffs
Debt was $7,504.2 million at September 30, 2026; U.S. tariffs and inventory charges on products to be discontinued by 2032 (about $170 million) cut FY2025 net earnings.
Regulatory transition
MDD-certified products must move to EU MDR by December 2027 or 2028; FDA compliance and healthcare cost containment are listed risks.

What leadership says

“we are no longer just a knee company”

Ivan Tornos, Chairman, President and CEO · Q3 2026 earnings call, November 4, 2026

“This is not a cost-savings strategy... This is a growth strategy. We want to have the best sales force in orthopedics”

Ivan Tornos, Chairman, President and CEO · Q2 2026 earnings call, August 5, 2026, on the U.S. sales force transition

“We don't call ourselves a robotic company. We call ourselves a technology company.”

Ivan Tornos, Chairman, President and CEO · Q2 2026 earnings call, August 5, 2026

“Our boldest chapter remains ahead”

Ivan Tornos, Chairman, President and CEO · Q3 2026 earnings call, November 4, 2026, ahead of the company's 100-year anniversary

Where a supplier can help

Sales enablement for a converted U.S. force
Tied to Project Optima: a sales force moving from independent reps to employees, with 200 tech reps being added and new incentive plans, needs onboarding, training, compensation and CRM tooling.
AI and process re-engineering
Tied to the opex efficiency priority: AI partners, shared services, demand planning, customer service and a global capability center in India are the named levers.
Manufacturing consolidation support
Tied to the Manufacturing Network Optimization Plan and the Costa Rica facility: equipment, automation and transfer services for sites consolidating into Warsaw and lower-cost geographies.
Acquisition integration
Tied to Paragon 28, Monogram and the three 2026 acquisitions, with more M&A planned from 2027: integration of systems, supply chains and commercial teams.
Regulatory compliance capacity
Tied to the EU MDR transition deadline of December 2027 or 2028 and FDA filings such as Monogram's 510(k).

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Zimmer Biomet?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Zimmer Biomet

What does Zimmer Biomet do?

It designs, manufactures and markets orthopedic products (knees, hips, sports medicine, extremities, trauma, CMFT), bone cement, surgical products and the ZBEdge robotic and digital platform, sold to surgeons, hospitals and ambulatory surgery centers.

What is Zimmer Biomet's revenue?

FY2025 net sales were $8,231.5 million, up 7.2%. In the first nine months of 2026 net sales were $6,326.6 million (+5.7%), and 2026 net sales growth guidance is 4.4% to 4.9%.

How many employees does Zimmer Biomet have?

About 17,000 at December 31, 2025, of which about 7,000 in the U.S., about 2,000 in R&D and about 6,000 in manufacturing.

Who leads Zimmer Biomet?

Ivan Tornos is Chairman, President and CEO (CEO since August 2023, Chairman since May 2025); Paul Stellato is interim CFO while a CFO search is under way.

What is Zimmer Biomet's strategy?

Converting the U.S. sales force to a dedicated, specialised organisation, fixing knees with robotics such as ROSA and Monogram, shifting R&D and M&A toward faster-growing markets, and cutting costs through restructuring and manufacturing consolidation.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)